But success is not guaranteed, and expectations should be tempered
Dosing Considerations and MHRA Safety Guidance In clinical trials, retatrutide was administered via weekly subcutaneous injection at escalating doses of 112 mg, but the MHRA has issued no prescribing guidance and warns against its use outside approved trial settings
Berglund LM, Lyssenko V, Ladenvall C, Kotova O, Edsfeldt A, Pilgaard K, Alkayyali S, Brons C, Forsblom C, Jonsson A, et al
Allergic (hypersensitivity) reactions: fever, skin rash, hives, sores in your mouth, blistering and peeling of your skin, swelling of your lymph nodes, swelling of your face, eyes, lips, tongue, or throat, trouble swallowing or breathing
You can use our Cymbiotika Expert Health Quiz to get a better sense of which nutrients your body might be craving based on your specific goals